Hutchison MediPharma Starts Phase I Trial of Fourth Cancer Molecule
February 22, 2012 at 07:13 AM EST
Hutchison MediPharma, the drug discovery company majority owned by Chi-Med, began a first-in-human Phase I clinical trial of a cancer drug, volitinib (HMPL-504), in Australia. Volitinib, the fourth cancer drug that the company has put into clinical trials, is a novel inhibitor of the c-Met receptor tyrosine kinase. In December 2011, Hutchison MediPharma entered a co-licensing agreement for the molecule with AstraZeneca in a $140 million deal. AstraZeneca assumed responsibility for developing volitinib outside of China. More details.... Stock Symbols: (AIM: HCM) (NYSE: AZN) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});